PBMs claim they help patients by negotiating lower prices from drug manufacturers. But the fact is PBMs rarely, if ever, pass those savings on to patients.
Folks may not be familiar with Pharmacy Benefit Managers, or PBMs, but they live with the effects of PBMs almost every time they go to fill a prescription and have to dig deep in their wallet to pay for it.
Please, let patients help improve healthcare. Let patients help steer our decisions, strategic and practical. Let patients help define what value in medicine is.
In my book, 'Let Patients Help,' one chapter is titled 'Let patients vote on what's worth the cost.' That's sensible, right? In other industries, consumer preference is a key determinant in prices.
Whenever you see shrinks on television, they're so clearly written by patients. They're either idealized or they're demonized or they love their patients. All they ever think about is their patients.
I support negotiating authority to lower prescription drug prices.
Lets take away the incentives to do 'to' patients and instead create incentives to do 'for' patients, to be 'with' patients. We don't need to do comparative effectiveness trials to see if that works; we can just ask patients.
There is an enormous amount of options that a physician can provide today, right down from curing patients, treating patients, or providing patients with psychic solace or pain relief. So, in fact, the gamut of medical intervention is enormous.
President Trump has exposed the dirty secret of drug pricing: There is a shadowy third player in the transaction between patients and their pharmacists: middlemen who have taken a big kickback from the drug manufacturer, which may or may not be reflected in patients' out-of-pocket costs.
I wasn't afraid of treating Ebola patients in the isolation unit. That was the safest job. But seeing patients in the clinic, seeing patients in the emergency room, being in the community - those things gave me pause.
I am a spiritual person. I'm a Catholic. I treat my patients, the dead patients, as live patients. I believe there is life after death. And I talk to my patients. I talk to them, not loudly but quietly in my heart when I look at them. Before I do an autopsy, I must have a visual contact with the face.
Pretty much everybody knows there are not enough organs for all of those patients who need to get transplants, and what happens is, is that organs are actually directed in liver transplantation to those patients who are the sickest. So the patients who have the greatest chance of dying in the next three months or so are the ones who get the priority for the liver transplant.
When the FDA forces an old drug off the market, patients have very little say in the matter. Patients have even less of a say when the FDA chooses not to approve a new drug. Instead, we are supposed to rely on the FDA's judgment and be grateful. But can the FDA really make a choice that is appropriate for everyone? Of course not.
The survival rate of Dr Burton's patients approximately doubled the maximum survival rate of conventionally treated patients. Had these findings pertained to a chemotherapy drug instead of IAT, massive amounts of funding would have been allocated to investigate the drug. Once again, the politics of cancer barred a potentially valuable treatment from reaching the public.
Some hospitals screen all ICU patients and isolate those with MRSA, a process that can be challenging for both caregivers and patients.
There are several patients - there are thousands of patients, tens of thousands of patients, that carry either a stimulator in the brain or in the periphery, in the inner ear, to restore neurological functions or to control diseases like Parkinson's disease.
Patients want to be seen as people. For me, the person's life comes first; the disease is simply one aspect of it, which I can guide my patients to use as a redirection in their lives. When doctors look at their patients, however, they are trained to see only the disease.